RetinalGenix Technologies (RTGN) Net Equity Issued and Repurchased (2020 - 2025)
RetinalGenix Technologies (RTGN) posted Net Equity Issued and Repurchased of $212000.0 for Q4 2025, up 116.23% sequentially from $98045.0 in Q4 2024, and up 116.23% YoY from $98045.0 in Q4 2024.
RetinalGenix Technologies (RTGN) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
RetinalGenix Technologies has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $212000.0 in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 116.23% year-over-year to $212000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $715089.0 (up 42.14% YoY) and the FY2025 annual result came in at $398000.0, down 20.89% from the prior year.
- Net Equity Issued and Repurchased advanced to $212000.0 in Q4 2025 per RTGN's latest filing, from $98045.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $398097.0 in Q1 2021 and troughed at $60500.0 in Q1 2022.
- A 4-year average of $206532.0 and a median of $212000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2022 and 2025: Net Equity Issued and Repurchased slumped 84.8% in 2022, then surged 116.23% in 2025.
- Over 4 years, Net Equity Issued and Repurchased stood at $258934.0 in 2021, then tumbled by 76.63% to $60500.0 in 2022, then jumped by 62.06% to $98045.0 in 2024, then soared by 116.23% to $212000.0 in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $212000.0, $98045.0, and $305044.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,000.00 |
| Dec 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 98,045.00 |
| Dec 31, 2024 | 98,045.00 |
| Sep 30, 2024 | 305,044.00 |
| Sep 30, 2024 | 305,044.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2022 | 60,500.00 |
| Mar 31, 2022 | 60,500.00 |
| Dec 31, 2021 | 258,934.00 |
| Dec 31, 2021 | 258,934.00 |
| Sep 30, 2021 | 162,792.00 |
| Sep 30, 2021 | 162,792.00 |
| Jun 30, 2021 | 263,376.00 |
| Jun 30, 2021 | 263,376.00 |
| Mar 31, 2021 | 398,097.00 |
| Mar 31, 2021 | 398,097.00 |
| Dec 31, 2020 | 343,810.00 |
| Dec 31, 2020 | 343,810.00 |